Nkarta, Inc.
nkartatx.comWhat Do They Do?
Develops engineered natural killer cell therapies for people with autoimmune diseases, including lupus nephritis, systemic sclerosis and myositis.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$40.4MView ↗
- ▲ +76% (Loss)
- vs −$23M in Q2 FY2025
Cancer to autoimmune diseases
The earlier report describes engineered NK cell therapies for cancer, including blood cancers and solid tumors. The latest report centers on autoimmune diseases; the oncology studies are closed to enrollment and deprioritized.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 25, 2026We are a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered…View ↗
NKX101 is currently being studied in a multi-center Phase 1 clinical trial in the United States for the treatment of relapsed or refractory…View ↗
Our NKX019 program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is found on these…View ↗
Who Do They Compete With?
Competes with AstraZeneca, Autolus, Bristol-Myers Squibb, Cabaletta, Cartesian, Gilead, iCell, Juventas, JW Therapeutics, Kyverna, Miltenyi, Novartis, Roche, Rui Therapeutics, Synthekine, Adicet, Allogene, Artiva, Atara, and CRISPR Therapeutics
10-K for FY2025, filed Mar 25, 2026A large number of biopharmaceutical companies are applying their technology and development capabilities to the field of B-cell mediated…View ↗
Loading...
